DE111, a spore-forming probiotic Bacillus subtilis strain from ADM, was recently approved by the Therapeutic Goods Administration (TGA) in Australia.
 
This news comes shortly after DE111 was also approved by the National Health Commission in China.
 
“This is an important milestone for ADM, as it marks the first Bacillus subtilis strain to be approved by the TGA in Australia,” said Helen Hu, president of health & wellness APAC at ADM. “By expanding access to DE111, we’re facilitating new innovation possibilities for our Australian customers, enabling the development of pioneering gut health-supporting products. Additionally, the continued approval of DE111 by important government authorities demonstrates its high quality, safety and alignment with strict regulatory standards.”
 
DE111 is clinically evidenced to support digestive health and immune function. It can survive through the stomach and germinate in the small intestine, and is substantiated to support a healthy gastrointestinal tract, gut function, and microbiome diversity.
 
“DE111 is a spore-forming probiotic, which means it can withstand harsh formulation environments that may otherwise damage conventional probiotics. This robustness is paving the way for new, convenient and enjoyable foods, beverages and dietary supplements that meet people where they are on their wellness journeys, especially as more consumers make the connection between their gut and digestive health and other aspects of well-being,” said Hu.
 
Citing consumer researcher FMCG Gurus, ADM reported that 81% of consumers in Australia recognize a link between digestive health and overall well-being, and 76% specifically see a connection between digestive health and immune function. A total of 64% of Australian consumers have used probiotics and cultures to address digestive health concerns over a 12-month window. Euromonitor also forecasts that the Australian probiotic supplement market is poised to grow by a 2.7% CAGR between 2023 and 2028.